Skip to main content
2025 DC/CSEM Professional Conference Main banner
On-Demand

Accredited Symposium

AS06 - From Screening to Treatment: A Practical Approach to MASLD Management in Individuals with Metabolic Disease

Saturday, November 29, 2025
09:15 - 10:30 Toronto
Location: Room 201 A/B/C/D/E/F

    Speaker(s)

  • Giada Sebastiani, MD FAASLD (she/her/hers)

    Professor of Medicine
    McGill University
    McGill University
    Montreal, Quebec, Canada

    Disclosure(s): Abbvie: Speaker/Honoraria (Terminated, November 4, 2025); Canada Drug Agency: Consultant (Terminated, November 4, 2025); Canadian Institutes of Health Research (CIHR): Grant/Research Support (Ongoing); CCRN: Speaker/Honoraria (Ongoing); Crohn's and Colitis Canada: Grant/Research Support (Ongoing); Eli Lilly: Speaker/Honoraria (Ongoing); FRQS: Grant/Research Support (Ongoing); Gilead: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); GlaxoSmithKline (GSK): Advisory Board (Ongoing); Lupin: Speaker/Honoraria (Ongoing); Merck: Speaker/Honoraria (Ongoing); Montreal General Hospital Foundation: Grant/Research Support (Ongoing); Novo Nordisk Canada: Advisory Board (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (Ongoing)

  • SW

    Shahebina Walji

    Disclosure information not submitted.

  • CB

    Chantal Bémeur

    Disclosure information not submitted.

    • Moderator(s)

  • Harpreet Singh Singh Bajaj, MD, MPH, ECNU, FACE

    Endocrinologist and Director of Late-Phase Research
    Endocrinologist, LMC Healthcare (Brampton) 2979 Bovaird Drive East, Brampton
    Brampton, Ontario, Canada

    Disclosure(s): Abbott: Grant/Research Support (Ongoing); Amgen: Grant/Research Support (Ongoing); Anji Pharmaceuticals: Grant/Research Support (Ongoing); Arrowhead Pharmaceuticals: Grant/Research Support (Ongoing); AstraZeneca: Grant/Research Support (Ongoing); Biomea: Grant/Research Support (Ongoing); Boehringer Ingelheim: Grant/Research Support (Ongoing); Eli Lilly: Grant/Research Support (Ongoing); GlaxoSmithKline: Grant/Research Support (Ongoing); Ionis Pharmaceuticals: Grant/Research Support (Ongoing); Kowa Pharmaceuticals: Grant/Research Support (Ongoing); Novartis: Grant/Research Support (Ongoing); Novo Nordisk: Grant/Research Support (Ongoing); Pfizer: Grant/Research Support (Ongoing)

Disclosure(s):
Giada Sebastiani: Abbvie: Speaker/Honoraria (Terminated, November 4, 2025); Canada Drug Agency: Consultant (Terminated, November 4, 2025); Canadian Institutes of Health Research (CIHR): Grant/Research Support (Ongoing); CCRN: Speaker/Honoraria (Ongoing); Crohn's and Colitis Canada: Grant/Research Support (Ongoing); Eli Lilly: Speaker/Honoraria (Ongoing); FRQS: Grant/Research Support (Ongoing); Gilead: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); GlaxoSmithKline (GSK): Advisory Board (Ongoing); Lupin: Speaker/Honoraria (Ongoing); Merck: Speaker/Honoraria (Ongoing); Montreal General Hospital Foundation: Grant/Research Support (Ongoing); Novo Nordisk Canada: Advisory Board (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (Ongoing)
Harpreet Singh Singh Bajaj, MD, MPH, ECNU, FACE: Abbott: Grant/Research Support (Ongoing); Amgen: Grant/Research Support (Ongoing); Anji Pharmaceuticals: Grant/Research Support (Ongoing); Arrowhead Pharmaceuticals: Grant/Research Support (Ongoing); AstraZeneca: Grant/Research Support (Ongoing); Biomea: Grant/Research Support (Ongoing); Boehringer Ingelheim: Grant/Research Support (Ongoing); Eli Lilly: Grant/Research Support (Ongoing); GlaxoSmithKline: Grant/Research Support (Ongoing); Ionis Pharmaceuticals: Grant/Research Support (Ongoing); Kowa Pharmaceuticals: Grant/Research Support (Ongoing); Novartis: Grant/Research Support (Ongoing); Novo Nordisk: Grant/Research Support (Ongoing); Pfizer: Grant/Research Support (Ongoing)

Learning Objectives:

  • Implement evidence-based screening protocols to identify patients at risk for MASLD and stratify their degree of hepatic fibrosis;
  • Integrate lifestyle modification strategies and pharmacological interventions into individualized management plans for patients with MASLD and concurrent metabolic disorders;
  • Apply a multidisciplinary approach to optimize cardiometabolic risk reduction in patients with MASLD while navigating practical challenges.